Passive immunization with influenza haemagglutinin specific monoclonal antibodies

Hum Vaccin Immunother. 2018;14(11):2728-2736. doi: 10.1080/21645515.2018.1489947. Epub 2018 Jul 16.

Abstract

The isolation of broadly neutralising antibodies against the influenza haemagglutinin has spurred investigation into their clinical potential, and has led to advances in influenza virus biology and universal influenza vaccine development. Studies in animal models have been invaluable for demonstrating the prophylactic and therapeutic efficacy of broadly neutralising antibodies, for comparisons with antiviral drugs used as the standard of care, and for defining their mechanism of action and potential role in providing protection from airborne infection.

Keywords: HA stem; Influenza; broadly neutralising antibodies; monoclonal antibodies; passive immunization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Neutralizing / pharmacology
  • Antibodies, Neutralizing / therapeutic use
  • Antibodies, Viral / pharmacology
  • Antibodies, Viral / therapeutic use*
  • Cross Protection / drug effects
  • Cross Protection / immunology
  • Disease Models, Animal
  • Drug Evaluation, Preclinical / methods
  • Hemagglutinin Glycoproteins, Influenza Virus / immunology
  • Hemagglutinin Glycoproteins, Influenza Virus / metabolism
  • Humans
  • Immunization, Passive / methods*
  • Influenza A virus / immunology*
  • Influenza, Human / therapy*
  • Mice
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Hemagglutinin Glycoproteins, Influenza Virus

Grant support

This work at the Melbourne WHO Collaborating Centre for Reference and Research on Influenza was supported by the Australian Government Department of Health.